ISOPP CAPhO 2025 Symposium: Enhancing Treatment Decision-Making in Lung Cancer: Real-World Evidence on Molecularly Guided Treatment Selection, Repeat Biopsy, Drug Sequencing, and Clinical Outcomes

This talk will explore how real-world evidence from the Australasian Longitudinal Cohort Study and Biobank (AURORA) and other international real-world cohorts is shaping regulatory decision-making and drug approvals while enhancing treatment decision-making in lung cancer. The presentation will address key topics such as the role of molecularly guided treatment selection, disparities between real-world and clinical trial outcomes, insights from repeat biopsy strategies, and the impact of drug sequencing on clinical outcomes. The discussion will emphasize the use of longitudinal data to inform personalized treatment strategies, optimize therapy selection and sequencing, and improve outcomes for patients, with a focus on oncogene driven lung cancers.

Learning Objectives

• Understand the importance of real-world evidence in advancing therapeutic strategies and informing regulatory decisions in lung cancer.
• Recognize disparities between real-world and clinical trial outcomes and their implications for clinical practice.
• Evaluate the role of repeat biopsy in tracking molecular changes and guiding treatment decisions.
• Explore the impact of drug sequencing approaches on long-term clinical outcomes in lung cancer management.